164
Participants
Start Date
April 24, 2017
Primary Completion Date
March 25, 2022
Study Completion Date
January 23, 2025
Nivolumab 240 mg
PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
Ipilimumab 1mg/kg
Ipilimumab 1 mg/kg every 3 weeks x 4
Nivolumab 3mg/kg
In combination with Ipilimumab
Nivolumab 360mg
Continue Nivolumab 360 mg IV every 3 weeks
Columbia University, New York
Univeristy of Pennsylvania, Philadelphia
Fox Chase Cancer Center, Philadelphia
Georgetown University, Washington D.C.
Winship Cancer Institute of Emory University, Atlanta
Cleveland Clinic, Cleveland
Northwestern University Feinberg Schooll Of Medicine, Chicago
University of Illinois Cancer Center, Chicago
University of Texas Southwestern Medical Center, Dallas
Yale University, Yale Cancer Center, New Haven
Beth Isreal Deaconess Medical Center, Boston
Hackensack University Medical Center, Hackensack
Collaborators (2)
Bristol-Myers Squibb
INDUSTRY
Hoosier Cancer Research Network
OTHER
Michael B. Atkins, MD
OTHER